{"id":511864,"date":"2021-07-12T09:47:01","date_gmt":"2021-07-12T13:47:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/"},"modified":"2021-07-12T09:47:01","modified_gmt":"2021-07-12T13:47:01","slug":"moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/","title":{"rendered":"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine<\/b><\/p>\n<p class=\"bwalignc\"><i>Delivery to begin in the first quarter of 2022<\/i><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com%2F&amp;esheet=52458284&amp;newsitemid=20210712005515&amp;lan=en-US&amp;anchor=Moderna%2C+Inc.&amp;index=1&amp;md5=5f55ae16e43149a5028a41ac50b91771\">Moderna, Inc.<\/a> (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the government of Argentina for 20 million doses of Moderna\u2019s COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized, to begin delivery in the first quarter of 2022.\n<\/p>\n<p>\n\u201cWe appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates,\u201d said St\u00e9phane Bancel, Chief Executive Officer of Moderna. \u201cWe are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine.\u201d\n<\/p>\n<p><b>About the COVID-19 Vaccine Moderna<\/b><\/p>\n<p>\nThe Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein. Moderna has received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adults from health agencies in more than 50 countries and an Emergency Use Listing (EUL) from the World Health Organization (WHO). Moderna has filed for emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adolescents with global health agencies.\n<\/p>\n<p><b>About Moderna<\/b><\/p>\n<p>\nIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna\u2019s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.\n<\/p>\n<p>\nModerna\u2019s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by <i>Science<\/i> for the past six years. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.modernatx.com&amp;esheet=52458284&amp;newsitemid=20210712005515&amp;lan=en-US&amp;anchor=www.modernatx.com&amp;index=2&amp;md5=70e90d54876c0b9b627c52e2e780bed7\">www.modernatx.com<\/a>.\n<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company\u2019s development of a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273, also referred to as COVID-19 Vaccine Moderna and the Moderna COVID-19 Vaccine), as well as booster vaccine candidates; the Company\u2019s agreement to supply the vaccine to the government of Argentina; and the anticipated number of doses and timing for delivery of vaccine supply. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading \u201cRisk Factors\u201d in Moderna\u2019s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52458284&amp;newsitemid=20210712005515&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=5fbdc488fe50e976df9ec367cad40adb\">www.sec.gov<\/a>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna\u2019s current expectations and speak only as of the date hereof.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210712005515\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210712005515\/en\/<\/a><\/span><\/p>\n<p><b>Moderna Contacts<\/p>\n<p>Media:<br \/>\n<\/b><br \/>Colleen Hussey<br \/>\n<br \/>Director, Corporate Communications<br \/>\n<br \/>617-335-1374<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Colleen.Hussey@modernatx.com\">Colleen.Hussey@modernatx.com<br \/>\n<\/a><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Lavina Talukdar<br \/>\n<br \/>Senior Vice President &amp; Head of Investor Relations<br \/>\n<br \/>617-209-5834<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Lavina.Talukdar@modernatx.com\">Lavina.Talukdar@modernatx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States South America Argentina North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Research Pharmaceutical Medical Supplies General Health Health Infectious Diseases Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210712005515\/en\/839474\/3\/KO_LOGO.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine Delivery to begin in the first quarter of 2022 CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the government of Argentina for 20 million doses of Moderna\u2019s COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized, to begin delivery in the first quarter of 2022. \u201cWe appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates,\u201d said St\u00e9phane Bancel, Chief Executive Officer of Moderna. \u201cWe are committed to making our vaccine available around the world as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511864","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine Delivery to begin in the first quarter of 2022 CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the government of Argentina for 20 million doses of Moderna\u2019s COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized, to begin delivery in the first quarter of 2022. \u201cWe appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates,\u201d said St\u00e9phane Bancel, Chief Executive Officer of Moderna. \u201cWe are committed to making our vaccine available around the world as &hellip; Continue reading &quot;Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T13:47:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine\",\"datePublished\":\"2021-07-12T13:47:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/\"},\"wordCount\":755,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/\",\"name\":\"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-12T13:47:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine - Market Newsdesk","og_description":"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine Delivery to begin in the first quarter of 2022 CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the government of Argentina for 20 million doses of Moderna\u2019s COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized, to begin delivery in the first quarter of 2022. \u201cWe appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates,\u201d said St\u00e9phane Bancel, Chief Executive Officer of Moderna. \u201cWe are committed to making our vaccine available around the world as &hellip; Continue reading \"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-12T13:47:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine","datePublished":"2021-07-12T13:47:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/"},"wordCount":755,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/","name":"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-12T13:47:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005515r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-supply-agreement-with-argentina-for-20-million-doses-of-its-covid-19-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511864"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511864\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}